Below is a consolidated account of the most notable insider buying and selling that was disclosed on Monday for publicly traded companies in the United States. The items are organized under top buys and top sells and report transaction details, subsequent holdings where available, and context from InvestingPro analysis as noted in the filings.
Top buys
CG Oncology, Inc. - On June 25, 2026, director Brian Guan-Chyun Liu purchased 371,085 shares of company stock at $66.87 per share, representing an outlay of about $24,814,453. Following that acquisition, Liu is reported to indirectly hold 1,886,236 shares through Seven Fleet Partners, LP. The company’s share price has since risen to $73.73, trading close to its 52-week high of $75.50. InvestingPro analysis included in the filings indicates that CGON appears overvalued relative to its Fair Value estimate, even as the stock has returned 177% over the prior year. The filing further notes that Mr. Liu, as the managing member of Seven Fleet Advisors, LLC - the investment manager of Seven Fleet Partners, LP - may be deemed to beneficially own the shares in question, though he disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.
Hammer Technology Holdings - Michael Cothill, the company’s chief executive officer, carried out multiple purchases of company shares in April and May 2026 that aggregate to roughly $2.74 million. The trades spanned prices between $0.10 and $0.264 per share. A notable filing shows that on May 25, 2026, Cothill acquired 10,154,542 shares of common stock at $0.264 per share. That purchase was executed indirectly via Caban Global Reach Private Equity LP, an entity in which he serves as general partner and managing member. After the May 25 transaction, his indirect ownership was reported as 14,504,542 shares. Hammer Technology’s shares are trading at $0.14 at the time of disclosure and had appreciated 32% in the preceding week. InvestingPro commentary included with the filings highlights that HMMR exhibits high price volatility and remains unprofitable over the last twelve months.
Nexstar Media Group, Inc. - On June 26, 2026, Perry A. Sook, Nexstar’s CEO and director, purchased 12,235 shares of the company’s common stock at $162.2647 per share, for a total consideration of approximately $1,985,308. After the transaction, Sook’s direct holdings in Nexstar common stock were reported at 899,044 shares, and his indirect holdings through PS Sook Ltd., of which he and his spouse are beneficial owners, were 975,956 shares. At the time of reporting, Nexstar’s shares traded at $165.58 and were positioned near their 52-week low of $154.47, with a year-to-date decline of 17.81%. InvestingPro analysis cited in the filing characterizes the stock as slightly overvalued relative to its Fair Value, while noting the company’s dividend yield of 4.54%.
Boundless Bio - Tang Capital Management LLC and Kevin Tang, the manager of the firm, disclosed purchases totaling 286,333 shares of Boundless Bio common stock across multiple transactions between June 25 and June 29, 2026. The combined cost of these purchases was $714,768, with per-share prices ranging from $2.47 to $2.56. Both Tang Capital Management LLC and Kevin Tang are reported as 10% owners of the company and acquired the shares indirectly through limited partnerships and corporate entities. According to InvestingPro data appended to the disclosure, Boundless Bio has returned 143% over the past year and 105% over the past six months. InvestingPro’s commentary referenced in the filing calls out the strong momentum and indicates the stock appears undervalued relative to its Fair Value estimate.
Jefferies Financial Group Inc. - An institutional-sized purchase was recorded in an amended Form 4 filing showing Sumitomo Mitsui Financial Group, Inc., which is deemed a director of Jefferies Financial Group, acquired 6,429,337 shares of common stock on May 1, 2026. The final adjusted price recorded for that transaction was $54.83 per share, representing a total outlay of approximately $352,520,547. The filing states the acquisition is attributed to SMFG because Mr. Hyakutome, Deputy President of SMFG, serves on Jefferies’ board of directors, and SMFG is considered a director for purposes of Section 16 of the Securities and Exchange Act of 1934. The timing is notable because Jefferies’ shares are trading at $47.86 at the time of this report, which is nearly 22% below the price at which SMFG completed its purchase and roughly 13% below the transaction price. InvestingPro’s analysis enclosed with the disclosure suggests Jefferies appears undervalued and that the Fair Value estimate implies meaningful upside potential.
Top sells
Hinge Health, Inc. - Insight Holdings Group, LLC and its affiliated investment funds disclosed substantial sales in two separate filings. On June 25, 2026, Insight entities reported selling 530,982 shares of Class A Common Stock for about $38.1 million. Those sales followed the conversion of an equal number of Class B Common Stock shares into Class A Common Stock on the same day. A subsequent filing on June 29, 2026 disclosed the sale of an additional 1,466,667 shares, which brought in about $121.5 million. The weighted average sale prices across those disposals were reported in a range from $81.305 to $84.59 per share. The trades were executed under a Rule 10b5-1 trading plan that Insight adopted on August 20, 2025. Since these transactions, Hinge Health’s price has moved to $81.48, trading just beneath its 52-week high of $84.62. InvestingPro’s assessment noted in the filings characterizes HNGE as appearing overvalued and among the platform’s most overvalued stocks.
Oscar Health, Inc. - Mark T. Bertolini, Oscar Health’s CEO and a director, sold 1,206,310 shares of Class A Common Stock across multiple transactions dated June 25 and June 26, 2026. The aggregate proceeds of those sales were approximately $34,912,078, with per-share prices between $28.06 and $30.17. The filings state these dispositions were made to satisfy tax withholding obligations tied to deferred settlement of performance stock units and time-based restricted stock units that vested on April 3, 2026. The sales were conducted pursuant to a Rule 10b5-1 trading plan that was initially established on November 10, 2025, and later amended and restated on March 24, 2026. The reported sale prices are close to the stock’s 52-week high of $30.38, at a time when shares have appreciated 105% over the last six months.
Workday, Inc. - David A. Duffield, a holder of 10% of Workday, reported selling 107,500 shares of Class A Common Stock on June 25, 2026, netting approximately $12.4 million. The sales followed the same-day conversion of 107,500 shares of Class B Common Stock into an equal number of Class A Common Stock. The reported sale prices ranged from $114.1416 to $118.7611 per share. Workday’s shares were trading at $123.56 at the time of disclosure, representing a 9.88% gain over the prior week but a 43% decline over the preceding six months. InvestingPro’s valuation commentary included with the filing indicates WDAY appears undervalued and ranks among the platform’s most undervalued stocks.
Broadcom Inc. - Mark Brazeal, Broadcom’s Chief Legal & Corporate Affairs Officer, sold 25,000 shares of the company’s common stock on June 25, 2026. The transaction totaled $9,675,000 at $387.0 per share. After the sale, Brazeal is reported to directly hold 244,989 shares of Broadcom common stock, a count that includes 123,750 restricted stock units. The disposition was disclosed in a Form 4 filing with the Securities and Exchange Commission on June 29, 2026.
Context and interpretation
These filings collectively illustrate a mixture of concentrated insider purchases and significant sales occurring under trading plans or to meet tax obligations. The purchases by corporate insiders and entities range from strategic sizable acquisitions, such as the $352.5 million institutional buy of Jefferies stock, to director-level purchases at growth-oriented biotech and technology companies. Conversely, some of the largest disposals were implemented through pre-arranged Rule 10b5-1 plans or arose from the mechanics of equity awards and tax requirements.
InvestingPro analysis, as referenced in the respective filings, provides a valuation overlay for several of the securities mentioned. That commentary flags instances where a stock appears overvalued relative to its Fair Value estimate, as well as cases where the stock appears undervalued. The filings also highlight other company-specific conditions such as large short-term price moves or negative profitability over a trailing twelve-month period.
Tracking insider transactions can offer investors additional context about how executives, directors, and large shareholders are managing their equity stakes. While purchases may be interpreted as a signal of confidence in a company’s prospects, sales can reflect varied motivations, including tax obligations, liquidity needs, or trades executed under pre-existing plans. Given the range of motives and structures documented in these filings, the transactions should be viewed as data points that may inform, but not determine, investment decisions.